Features and outcomes of pediatric early T cell leukemia: King Hussein Cancer Center experience  by Madanat, Faris et al.
Hematol Oncol Stem Cell Ther (2016) 9, 126–128Avai lab le at www.sc iencedi rect .com
ScienceDirect
journal homepage: www.elsevier .com/ locate /hemoncLETTER TO EDITORFeatures and outcomes of pediatric early T
cell leukemia: King Hussein Cancer Center
experiencehttp://dx.doi.org/10.1016/j.hemonc.2015.09.001
1658-3876/ 2015 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
* Corresponding author at: King Hussein Cancer Center, Queen
Rania Al Abdullah Street, P.O. Box 1269 Al-Jubeiha, Amman 11941,
Jordan. Tel.: +962 (6) 5300460x1388; fax: +962 (6) 5353001.
E-mail address: fmadanat@khcc.jo (F. Madanat).Faris Madanat *, Hiba Jaber, Ismaeel Azayyat, Nazmi Kamal,
Fareed Barakat, Khaldoun Al-Kayed, Rawad RihaniPediatric Department Hematology-Oncology at King Hussein Cancer Center, Amman, JordanReceived 30 June 2015; accepted 9 September 2015
Available online 25 September 2015To the Editor:
Acute lymphoblastic leukemia (ALL) accounts for about
25% of all childhood ALL. The incidence of ALL is about 4/
100,000 children, 85% of childhood ALL originate from B cell
precursors, and 15% are of T-cell origin. The incidence of
early T cell leukemia (ETCL), a subclass of T-cell acute lym-
phoblastic leukemia, varies from 5.5%, as reported by the
Tokyo children cancer study group L99-15 study, to about
16% in the AIEOP-BFM ALL2009 study and the UKALL 2003
protocol [1–3]. Several reports have shown conflicting
results regarding the prognosis of this subtype. Children
with ETCL were treated as T-cell ALL by all groups that
reported on the outcome [1–6].
We retrospectively reviewed 559 pediatric patients with
ALL diagnosed between Jan 2003 and December 2014. T cell
ALL accounted for 82 cases (14.7%). Complete immunophe-
notypic data was available for 63 (76.8%). ETCL accounted
for 20.6% (n = 13), and they form the study group (Table 1).In the non ETCL group; the median age was 9.25
(range 0.58–17.7 years). Males accounted for 70%
(n = 35). Median WBC at presentation was 128.1  103
(range 0.9–467  103). Four patients had CNS II status,
and one patient had CNS III. Forty two patients (84%)
were in remission at day 15 and 49 (98%) were in remis-
sion at end of induction; one patient had undetermined
status. With a median follow up of 21.6 months (range,
0.83–121.9), 5 had relapsed and died because of their
disease, 2 died because of sepsis ,and one due to
unknown cause.
The ETCL group had a median age of 10.8 (range 3.3–
14.4 years). Males accounted for 69% (n = 9). Median WBC
at presentation was 117.6  103 (range 2.7–240  103).
Four patients had CNS II status, and two had CNS III 3.
MRD, status of remission and therapy was administered
according to a modified St. Jude total XV protocol,
detailed of which were published earlier [7]. Nine
patients (69.2%) were in remission at day 15 and twelve
patients (92.3%) were in remission at end of Induction.
At a median follow up of 27.6 months (range 13.9–
93.7), two patients (15.4%) relapsed and died of their
disease (one with BM and CNS relapse, and the second
with BM relapse only. 11 patients (84.6%) remain in
remission.
Table 1 Characteristics and outcomes of early T-cell precursor acute leukemia and non-early T-cell precursor acute leukemia.
Characteristics of patients ETP T-cell ALL Non-ETP T-cell ALL p
No. of patients 13 50
Age (y) 10.8 (3.3–14.4) 9.25 (0.58–17.7) .68
WBC at presentation 17.6 * 103(2.7–240 * 103) 128.1 * 103 (0.9–467 * 103) .39
Remission on Day 15 9 (69.2) 42 (84) .25
Remission at end of induction 12 (92.3) 49 (98) .37
Median follow-up (mo) 27.6 (13.9–93.7) 21.6 (0.83–121.9) .19
Relapse 2 (15.4) 5 (7.9) .72
Data are presented as n (%) or median (range).
Note: ETP T-cell ALL = early T-cell precursor acute leukemia; mo = month; WBC = white blood cells; y = year.
Figure 1 Overall survival of early T-cell and nonearly T-cell acute lymphoblastic leukemia. Note: ALL = acute lymphoblastic
leukemia; CI = confidence interval; NA = not applicable.
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77.1% and 79.6% respectively, while the OS and EFS for
the non ETCL were 78.5% and 65.2% respectively.
In conclusion our data shows that ETC does not have infe-
rior outcome to that of the non-early T-cell group. A limita-
tion of this report is the small number of patients. A larger
number with long follow up is needed to determine the
prognosis of this subtype of T-cell ALL.References
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